An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies

URL

https://www.cell.com/cell/fulltext/S0092-8674(21)00662-0

Authors

Yafei Liu, Wai Tuck Soh, Jun-ichi Kishikawa, Mika Hirose, Emi E. Nakayama, Songling Li, Miwa Sasai, Tatsuya Suzuki, Asa Tada, Akemi Arakawa, Sumiko Matsuoka, Kanako Akamatsu, Makoto Matsuda, Chikako Ono, Shiho Torii, Kazuki Kishida, Hui Jin, Wataru Nakai, Noriko Arase, Atsushi Nakagawa, Maki Matsumoto, Yukoh Nakazaki, Yasuhiro Shindo, Masako Kohyama, Keisuke Tomii, Koichiro Ohmura, Shiro Ohshima, Toru Okamoto, Masahiro Yamamoto, Hironori Nakagami, Yoshiharu Matsuura, and Atsushi Nakaga

Published Date

May 24, 2021

Publication

Cell

User License: Elsevier user license | Elsevier's open access license policy

Elsevier user licenses
https://www.elsevier.com/en-gb/about/policies-and-standards/open-access-licenses/elsevier-user

Medium

document

Topics

adverse events,antibody dependent enhancement (ADE),COVID-19,gene therapy,mRNA,SARS-CoV-2 spike protein,vaccine systemic and virological concerns,vaccines